Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Non-cash Items: 2021-2024

Historic Non-cash Items for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $71.5 million.

  • ARS Pharmaceuticals' Non-cash Items fell 55.40% to $59.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.8 million, marking a year-over-year decrease of 55.40%. This contributed to the annual value of $71.5 million for FY2024, which is 185.10% up from last year.
  • ARS Pharmaceuticals' Non-cash Items amounted to $71.5 million in FY2024, which was up 185.10% from $25.1 million recorded in FY2023.
  • In the past 5 years, ARS Pharmaceuticals' Non-cash Items registered a high of $11.4 billion during FY2021, and its lowest value of $25.1 million during FY2023.
  • In the last 3 years, ARS Pharmaceuticals' Non-cash Items had a median value of $60.4 million in 2022 and averaged $52.3 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first tumbled by 99.47% in 2022, then skyrocketed by 185.10% in 2024.
  • ARS Pharmaceuticals' Non-cash Items (Yearly) stood at $11.4 billion in 2021, then plummeted by 99.47% to $60.4 million in 2022, then slumped by 58.51% to $25.1 million in 2023, then surged by 185.10% to $71.5 million in 2024.